Related search

Adjuvant Ipilimumab in High-Risk Uveal Melanoma

Cancers
Cancer ResearchOncology
2019English

Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Clinical Cancer Research
Cancer ResearchOncology
2018English

Adjuvant Chemotherapy Improves Survival of Patients With High-Risk Upper Urinary Tract Urothelial Carcinoma: A Propensity Score-Matched Analysis

BMC Urology
MedicineReproductive MedicineUrology
2017English

Effects of Topical and Subconjunctival Bevacizumab in High-Risk Corneal Transplant Survival

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2010English

Specialized Surveillance for Individuals at High Risk for Melanoma

JAMA Dermatology
DermatologyMedicine
2015English

Survival Analysis of Risk Factors for Major Recurrence of Intracranial Aneurysms After Coiling

Canadian Journal of Neurological Sciences
MedicineNeurology
2015English

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival

Clinical Cancer Research
Cancer ResearchOncology
2010English

A Phase III Study (CheckMate 238) of Adjuvant Immunotherapy With Nivolumab (NIVO) Versus Ipilimumab (IPI) After Complete Resection of Stage IIIb/c or Stage IV Melanoma (MEL) in Patients (Pts) at High Risk for Recurrence

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy